US4469631A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Fusion peptides comprising an expressible bacterial gene and β-endorphin
Assignee: University of California, San Diego
•
Filing: 1982-06-10
•
Granted: 1984-09-04
•
Expires: 2002-06-10
Abstract
Abstract DNA comprising the naturally occurring nucleotide sequence coding for amino acids 44-90 of beta -lipotropin and including the entire coding region for beta -endorphin with the exception of the C-terminal glutamine was modified, transferred to an expression transfer vector, and expressed as a fusion protein. The fusion protein was further modified in vitro to yield mature beta -endorphin. beta -endorphin was purified from a bacterial lysate. The structure and biological activity of the resulting product was proven by immunological assay, and by two independent assays designed to demonstrate biological activity.
Inventors
- 👤 John D. Baxter
- 👤 Ivy Fettes
- 👤 John Shine
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 11:31
CPC Classifications
C; C12; C12P; C12P21/00; C12P21/02; C12N; C12N1/00; C12N1/20; C12N1/205; C12N15/00; C12R; C12R2001/00; C12R2001/01; C12R2001/185; C12R2001/19; Y; Y10; Y10S; Y10S530/00; Y10S530/808
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
134 words
A fusion peptide, the synthesis of said peptide being directed by a DNA fragment consisting essentially of a DNA transfer vector having an expressible bacterial gene and having inserted therein a nucleotide sequence comprising naturally-occurring codons coding for β-endorphin or identifiable portion thereof having opiate agonist or antagonist activity, said nucleotide sequence comprising a naturally-occurring mammalian sequence coding for said β-endorphin or said identifiable portion thereof and being followed by a stop codon selected from the group consisting of TGA, TAA and TAG, said stop codon for a COOH-terminal amino acid of said β-endorphin or of said identifiable portion thereof, said nucleotide sequence being inserted in such orientation with respect to said bacterial gene that expression of said gene results in synthesis of a fusion peptide comprising said β-endorphin or said identifiable portion thereof.
Claim 2
Dependent Claim
134 words
A fusion peptide, the synthesis of said peptide being directed by a DNA fragment consisting essentially of a DNA transfer vector having an expressible bacterial gene and having inserted therein a nucleotide sequence comprising naturally-occurring codons coding for β-endorphin or identifiable portion thereof having opiate agonist or antagonist activity, said nucleotide sequence comprising a naturally-occurring mammalian sequence coding for said β-endorphin or said identifiable portion thereof and being followed by a stop codon selected from the group consisting of TGA, TAA and TAG, said stop codon for a COOH-terminal amino acid of said β-endorphin or of said identifiable portion thereof, said nucleotide sequence being inserted in such orientation with respect to said bacterial gene that expression of said gene results in synthesis of a fusion peptide comprising said β-endorphin or said identifiable portion thereof.
Claim 3
Dependent Claim
24 words
The fusion peptide of claim 1, synthesized by a microorganism bearing a DNA transfer vector comprising said DNA fragment coding for said fusion peptide.
Claim 4
Dependent Claim
18 words
The fusion peptide of claims 1 or 2 wherein said β-endorphin is mouse β-endorphin or identifiable portion thereof.
Claim 5
Dependent Claim
18 words
The fusion peptide of claims 1 or 2 wherein said β-endorphin is human β-endorphin or identifiable portion thereof.
Claim 6
Dependent Claim
36 words
The fusion peptide of claim 1 wherein said β-endorphin sequence or identifiable portion thereof having opiate agonist or antagonist activity comprises the -COOH terminal part of said fusion peptide and is preceded by an arginine residue.
Claim 7
Dependent Claim
27 words
The fusion peptide of claim 5 wherein lysine residues of said fusion peptide are protected from attack by trypsin by reaction with an amino group blocking agent.
Claim 8
Dependent Claim
15 words
The fusion peptide of claim 6 wherein the amino group blocking agent is citraconic anhydride.
References Cited (Backward Citations)
US4098778A
Cited
US4096237A
Cited
US4196122A
Cited
US4105652A
Cited
US4103005A
Cited
US4250087A
Cited
US4350764A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-09-04 | 1988-03-05 | 1988-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-09-04 | 1992-03-05 | 1992-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-09-04 | 1996-03-05 | 1996-09-04 | $7700.00 | Window Closed / Lapsed |